OMEICOS
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Total raised
€17M
€17,000,000
Funding rounds
1
Investors
3
distinct backers
Active since
2018-09
latest 2018-09
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood19
base rate 51% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-10-01 | Series C | €17M | Forbion Capital Partners,SICAR,Vesalius Biocapital Partners | View deal → |
Related news
Similar companies
same sector or country- Delivery Hero€7.3BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Celonis€2.1BGermany · Software